Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more
Vicore Pharma Holding AB (publ) (VICO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.074x
Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has a cash flow conversion efficiency ratio of -0.074x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-81.48 Million) by net assets (Skr1.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vicore Pharma Holding AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Vicore Pharma Holding AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vicore Pharma Holding AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hampidjan hf
IC:HAMP
|
0.016x |
|
PHC Holdings Corporation
PINK:PHCCF
|
0.087x |
|
Korea Electronic Power Industrial Development Co Ltd
KO:130660
|
0.072x |
|
Blue Foundry Bancorp
NASDAQ:BLFY
|
-0.001x |
|
Seche Environnem.
PA:SCHP
|
0.184x |
|
InnovAge Holding Corp
NASDAQ:INNV
|
0.089x |
|
Humacyte Inc
NASDAQ:HUMA
|
5.031x |
|
Global Indemnity Group, LLC Class A Common Stock
NASDAQ:GBLI
|
0.000x |
Annual Cash Flow Conversion Efficiency for Vicore Pharma Holding AB (publ) (2012–2025)
The table below shows the annual cash flow conversion efficiency of Vicore Pharma Holding AB (publ) from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.10 Billion | Skr-374.44 Million | -0.342x | -134.02% |
| 2024-12-31 | Skr1.13 Billion | Skr-164.95 Million | -0.146x | +73.35% |
| 2023-12-31 | Skr455.39 Million | Skr-249.58 Million | -0.548x | +47.17% |
| 2022-12-31 | Skr289.08 Million | Skr-299.92 Million | -1.037x | -49.97% |
| 2021-12-31 | Skr383.32 Million | Skr-265.17 Million | -0.692x | -104.48% |
| 2020-12-31 | Skr354.51 Million | Skr-119.94 Million | -0.338x | -25.06% |
| 2019-12-31 | Skr321.60 Million | Skr-87.00 Million | -0.271x | -133.73% |
| 2018-12-31 | Skr285.44 Million | Skr-33.04 Million | -0.116x | -69.69% |
| 2017-12-31 | Skr112.97 Million | Skr-7.71 Million | -0.068x | +28.89% |
| 2016-12-31 | Skr75.60 Million | Skr-7.25 Million | -0.096x | -113.43% |
| 2015-12-31 | Skr81.93 Million | Skr-3.68 Million | -0.045x | +14.58% |
| 2014-12-31 | Skr53.70 Million | Skr-2.83 Million | -0.053x | -17.40% |
| 2013-12-31 | Skr40.01 Million | Skr-1.79 Million | -0.045x | +29.52% |
| 2012-12-31 | Skr26.25K | Skr-1.67K | -0.064x | -- |